MediciNova Announces That The National Institutes Of Health Neurological Disorders And Stroke Has Awarded $22M For An Intermediate Size Expanded Access Protocol To Evaluate The Efficacy Of MN-166 In Amyotrophic Lateral Sclerosis
Express News | MediciNova Inc - Nih Awards $22 Million for Eap to Evaluate Mn-166 in ALS
Express News | Medicinova to Support Nih-Funded Expanded Access Clinical Trial to Evaluate Mn166 (Ibudilast) in Amyotrophic Lateral Sclerosis (ALS)
medicinova and others continue to rank in, with the start of clinical trials targeting ALS (amyotrophic lateral sclerosis).
Medicinova <4875> ranked in (as of 10:32 am). Significantly up. On the 23rd of yesterday, they announced that they have received new funding from the National Institutes of Health (NIH) in the United States for the Expand Access Program, a program implemented from a humanitarian perspective. The company has announced the start of clinical trials targeting ALS patients with MN-166 (Ibudilast), which they are developing, becoming a potential buying catalyst. Details are being coordinated with relevant organizations.
Volume change rate ranking (9:00) - Rain, Wind, Sun, Ange's, etc. are ranked.
* In the volume change rate ranking, you can understand the interest of market participants, such as the trend of trading, by comparing the average volume of the recent 5 days with the volume on the delivery day. * Top Volume Change Rate [As of September 20th, 9:32] (Comparison of average volume of the recent 5 days) Stock code Stock name Volume 5-day average volume Volume change rate Stock price change rate <9058> Tracom 542,400 107,185.08 248.86% 0.007
MediciNova: Confirmatory letter.
MediciNova: Interim report
Three points to watch in the afternoon session ~ due to the decline in US stocks and the strengthening of the yen, the decline temporarily exceeded 1,500 yen.
In the afternoon trading on the 4th, the following three points should be noted: - The Nikkei average fell sharply, with the decline temporarily exceeding 1500 yen due to the decline in US stocks and the appreciation of the yen. - The dollar-yen rate slowed its decline, and there were also buybacks due to the feeling of being reasonably priced. - Tokyo Electron (<8035>) was the top contributor to the rise in value, with Advantest (<6857>) coming in second. The Nikkei average fell sharply due to the decline in US stocks and the appreciation of the yen, with a decrease of 1280.72 yen (3.31%) compared to the previous day, to 37,405.
Express News | Medicinova Announces Acceptance of Abstract Regarding Mn-166 (Ibudilast) in Combat-ALS Clinical Trial for Presentation at the 2024 Annual Neals (Northeast Amyotrophic Lateral Sclerosis Consortium) Meeting
Sector Update: Health Care Stocks Rise Late Afternoon
MediciNova Shares Are Trading Higher After the Company Announced That It Received a Notice of Allowance From the U.S. Patent and Trademark Office for a Pending Patent Application, Which Covers MN-166 for Post-COVID Conditions.
Sector Update: Health Care Stocks Softer in Afternoon Trading
Sector Update: Health Care
MediciNova Shares Rise as Post-COVID Drug Due to Receive US Patent
MediciNova Gains After Patent Win for Long COVID Therapy
Reported Earlier, MediciNova Receives U.S. Patent Allowance For MN-166, Ensuring Broad Protection For Post-COVID Treatment Through 2042
Three points to watch in the afternoon session ~ rebound but temporary halt at the 75-day moving average.
In the afternoon of the 30th, the following 3 points are worth noting in the trading: - The Nikkei Average rebounded, but paused at the 75-day moving average - The dollar-yen is firm, hovering around 144 yen - The top contributors to the price increase are Advantest <6857> and Softbank Group <9984>. The Nikkei Average rebounded, but paused at the 75-day moving average. It rebounded with an increase of 222.90 yen (+0.58%) to 38,585.43 yen (with a trading volume of approximately 710 million shares) at the end of the morning session.
MediciNova (NASDAQ:MNOV) Is In A Good Position To Deliver On Growth Plans
Stocks that hit the daily limit up or down in the morning session.
■ Stock limit up <1743> Koatsu Kogyo <4059> MagMag <4316> B-Map <4584> KidsWell-Bio <4875> Medicinova <5025> Mercury Realtech Innovator <5242> Eyes ■ Stock limit down * Including temporary stock limit up/down (indicated value)
MediciNova: FY Dec 2024 Q2 (interim) results under US GAAP (consolidated)